Gemina Laboratories Ltd.
GLABF
$0.77
$0.03384.59%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.50M | 1.62M | 1.76M | 1.93M | 2.01M |
| Depreciation & Amortization | -- | -- | -- | -- | 23.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.62M | 2.66M | 3.18M | 3.86M | 4.54M |
| Operating Income | -2.62M | -2.66M | -3.18M | -3.86M | -4.54M |
| Income Before Tax | -2.51M | -2.74M | -3.22M | -3.87M | -4.76M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.51 | -2.74 | -3.22 | -3.87 | -4.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.51M | -2.74M | -3.22M | -3.87M | -4.76M |
| EBIT | -2.62M | -2.66M | -3.18M | -3.86M | -4.54M |
| EBITDA | -2.61M | -2.65M | -3.16M | -3.84M | -4.53M |
| EPS Basic | -0.03 | -0.04 | -0.04 | -0.05 | -0.07 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.03 | -0.03 | -0.04 |
| EPS Diluted | -0.03 | -0.04 | -0.04 | -0.05 | -0.07 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.03 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 296.43M | 295.25M | 295.03M | 291.50M | 280.88M |
| Average Diluted Shares Outstanding | 296.43M | 295.25M | 295.03M | 291.50M | 280.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
